AGC Biologics Doubles Mammalian Manufacturing Capacity with New Copenhagen Facility
TL;DR
AGC Biologics completed a new manufacturing building in Copenhagen, doubling mammalian manufacturing capacity, giving them a competitive edge in the biopharmaceutical CDMO industry.
The new facility at AGC Biologics Copenhagen uses the latest mammalian systems and single-use technology, including a production line with eight 2,000 L bioreactors and dedicated quality control laboratory spaces.
AGC Biologics' new manufacturing building will allow them to produce more treatments than ever before, contributing to the development of life-saving therapies and making the world a better place.
AGC Biologics' successful completion of the final milestone at its new manufacturing building in Copenhagen marks a significant advancement in biopharmaceutical manufacturing technology.
Found this article helpful?
Share it with your network and spread the knowledge!
AGC Biologics, a global leader in biopharmaceutical contract development and manufacturing, has officially launched operations at its new cutting-edge manufacturing facility in Copenhagen after receiving authorization from the Danish Medicines Agency. This expansion marks a significant milestone in the company's growth strategy and enhances its capacity to meet the increasing demand for biopharmaceutical production in Europe.
The new four-story, 19,000 square meter building has effectively doubled AGC Biologics' mammalian manufacturing capacity at its Copenhagen site. Equipped with the latest mammalian systems and single-use technology, the facility boasts a production line featuring eight 2,000-liter bioreactors, two downstream suites, and dedicated warehouse and quality control laboratory spaces. This substantial increase in capacity positions AGC Biologics as a formidable player in the European contract development and manufacturing organization (CDMO) market.
The importance of this expansion cannot be overstated in the context of the rapidly growing biopharmaceutical industry. With the rising demand for complex biologics and the increasing number of drugs in clinical trials, CDMOs play a crucial role in bringing new treatments to market. AGC Biologics' enhanced capabilities will allow it to support more pharmaceutical companies in their drug development and production efforts, potentially accelerating the availability of new therapies for patients worldwide.
Andrea Porchia, General Manager of the Copenhagen site, emphasized the significance of this achievement, stating that the facility is now poised to produce more treatments than ever before. The strategic location and expanded capacity make AGC Biologics an attractive partner for developers seeking CDMO services in Europe, potentially drawing more biopharmaceutical investment and innovation to the region.
The Copenhagen site's track record in supporting drug substance projects using both mammalian and microbial systems, along with its experience in producing seven commercial products, further strengthens AGC Biologics' position in the market. This expansion not only enhances the company's ability to serve its clients but also contributes to the broader biopharmaceutical ecosystem by increasing the overall manufacturing capacity available to drug developers.
As the biopharmaceutical industry continues to evolve, with a growing focus on personalized medicine and advanced therapies, the additional capacity and state-of-the-art capabilities of AGC Biologics' new facility will play a vital role in supporting the next generation of innovative treatments. This development represents a significant step forward in enhancing the global biopharmaceutical supply chain and reinforces Europe's position as a key hub for biomanufacturing excellence.
Curated from News Direct
